Draft evidence report reviewing ovarian cancer drugs

13 July 2017

The US non-profit Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the comparative clinical effectiveness and value of three poly ADP-ribose polymerase (PARP) inhibitors for treatment of ovarian cancer.

The three drugs covered are: Lynparza (olaparib), from AstraZeneca (LSE: AZN)); Rubraca (rucaparib), from Clovis Oncology (Nasdaq: CLVS); and Zejula (niraparib, from Tesaro (Nasdaq: TSRO). The report, along with draft voting questions, will be open to public comment for four weeks.

The ICER says it is committed to engaging with all stakeholders in a thorough and transparent manner. Before completing this Draft Evidence Report, ICER reached out to key stakeholders, including patient groups, clinical experts, and the manufacturers of the drugs to engage them in the process. ICER also accepted public comments on a Draft Scoping Document prior to conducting the review. The current draft report incorporates input received from patients, clinicians, manufacturers, and other stakeholders during each of these opportunities for engagement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK